CRISPR Cas9 genome editing has transformed the way scientists approach gene therapy, acting like precise DNA scissors that can target and repair hereditary diseases at the genetic level. This ...

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue ...

Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP ...

CRISPR is a breakthrough technology with humble origins. Scientists first discovered the powerful gene editor in bacteria that were using it as a weapon against invading viruses called phages. Phages ...

Rodolphe Barrangou, PhD, is the T. R. Klaenhammer Distinguished Professor at North Carolina State University, where he leads the CRISPR Lab. Rodolphe spent nine years at Danisco and DuPont, where he ...

Specialist investor NOVA Infrastructure has amassed $1.45 billion to back midsize operators of assets such as data centers, battery projects and water-management systems, as the firm looks to benefit ...

Intel's "HX" processors have, for several generations now, been its top-end laptop silicon. That's because they hold a little secret: they're not really laptop-specific silicon, exactly. Instead, the ...

Since the landmark discovery that a bacterial defense mechanism could be repurposed into programmable “molecular scissors,” CRISPR-Cas9 gene-editing technology has undergone a major evolution. Over ...

Now is the time to choose between recklessness and prudence On July 16, 1945, when the world’s first nuclear explosion shook the plains of New Mexico, J. Robert Oppenheimer, who led the project, ...

An invisible, unpredictable atmospheric force is wreaking havoc across the globe, sinking superyachts and bringing down planes. Follow scientists as they race to understand these catastrophic weather ...